Julian Cooney

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

Timothy P. Hughes, Susan Branford, Deborah L. White et al. · Blood · 2008 · 177 citations · Full text

RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML

Anna Brown, Peer Arts, Catherine Carmichael et al. · Blood Advances · 2020 · 150 citations · Full text

Allelic Variant, Developmental Biology, Somatic Mutations +15

Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study

Richard Herrmann, Marian Sturm, Kathryn Shaw et al. · International Journal of Hematology · 2011 · 97 citations

Regenerative Medicine, Cell Therapy, Transplantation +14

A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis

Glen Kennedy, Siok‐Keen Tey, Luke Buizen et al. · Blood · 2021 · 48 citations · Full text

Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study

David B. Miklos, Mohammad Abu Zaid, Julian Cooney et al. · Journal of Clinical Oncology · 2023 · 46 citations · Full text